Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP antagonists

- PMLiVE

FDA approves migraine headband

STX-Med’s electronic Cefaly device offers drug-free treatment option

Teva Pharma logo

Teva launches first inhaled antipsychotic in US

Adasuve available for the treatment of agitation associated with schizophrenia or bipolar disorder

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

Teva faces US marketing investigation

Department of Justice to probe promotion tactics for Copaxone and Azilect

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

- PMLiVE

Lilly agrees two antibody deals

Signs agreements with Genmab and Arteaus Therapeutics

- PMLiVE

Teva names Vigodman CEO and makes bid for NuPathe

Israeli pharma company confirms Jeremy Levin’s replacement

- PMLiVE

Key Teva shareholder backs Vigodman as next CEO

Board director tipped to replace Jeremy Levin at Israeli pharma firm

- PMLiVE

Teva’s vice chair steps down

Amir Elstein to take over from Moshe Many

- PMLiVE

Teva expects big things from improved drug programme

Aims to market enhanced versions of existing medicines

- PMLiVE

Teva withdraws US filing for cancer biologic

FDA requests more data for balugrastim

- PMLiVE

Change at the top as Levin leaves Teva

CEO resigns amid company-wide restructure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links